A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer.

Trial Profile

A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2012

At a glance

  • Drugs Bevacizumab; Cisplatin; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2008 Results published in Invest New Drugs 1 Apr 2008 [Epub ahead of print].
    • 06 Nov 2007 Status change from recruiting to in progress
    • 15 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top